Intuitive Surgical (ISRG) Stock Down 40%: Buy the Dip?

Key takeaways

Intuitive Surgical's fundamentals remain strong with growing procedures, revenue, and installed base, yet the stock has depreciated significantly, perhaps due to market re-pricing.
Recurring revenue from instruments and accessories forms a stable, high-margin part of the business, supporting long-term growth potential.
Headwinds like ACA subsidy expirations, hospital capital constraints, and industry cost pressures could limit growth, but the company maintains a cautiously optimistic outlook.
Valuation models suggest this dip might be an opportunity for long-term investors, but potential macroeconomic and industry risks require careful consideration.

Summary

Intuitive Surgical's Recent Performance and Market Revaluation

This section discusses the recent earnings report of Intuitive Surgical, highlighting strong financial metrics such as revenue growth, procedure volume, and installed base expansion. Despite these positives, the stock has plummeted over 40% from its highs, with the webinar emphasizing that market sentiment is currently re-evaluating the company's valuation. The analysis covers the stock's poor five-year CAGR of just 1.7% versus the robust growth of key business metrics, indicating a market correction or re-rating perhaps driven by broader economic or sector-specific concerns.

Product Growth and Revenue Breakdown

Focusing on operational details, this section features the company's product lines, such as DaVinci surgical systems and the newer ION platform for lung procedures. Procedure growth is strong, with 15% year-over-year increase and a significant installed base of nearly 12,000 systems worldwide. Revenue sources are broken down into recurring instruments and accessories, systems, and services, emphasizing that instruments and accessories account for about 75% of recurring revenue, highlighting the stability of this income stream. Comments on geographic expansion, production advancements, and the importance of the emerging markets are also included.

Challenges and Headwinds Facing Intuitive Surgical

This part reviews headwinds impacting the company's growth prospects, particularly from changes in U.S. healthcare policy and economic factors. The expiration of ACA subsidies appears to cause a decline in elective procedures, as some patients opt out of insurance due to cost. Additionally, potential impacts from hospital capital spending constraints, increased costs from semiconductor shortages, and competition are discussed. Management’s optimistic stance about U.S. healthcare spending and market stability is noted, but the discussion retains a cautious tone about ongoing headwinds.

Future Outlook and Investment Scenarios

The section presents forecasts for 2026, including procedure growth guidance and earnings estimates, tied into a reverse discounted cash flow analysis to evaluate if the current stock price implies overly optimistic growth assumptions. Several scenarios are considered, including slower growth due to healthcare system issues, moderate growth with longer timelines, and a broader market rotation away from healthcare stocks. The analysis underscores that, at current levels, the stock may present a 'buy the dip' opportunity, especially given the company's solid balance sheet and growth initiatives, but it remains a nuanced decision for investors.

Show notes

Intuitive Surgical posted double-digit growth in revenue, procedures, and installed base but ISRG stock is down over 40% from its highs. We dig into why the market is repricing this healthcare stock despite strong fundamentals.

Da Vinci procedure growth came in at 15% year-over-year, the installed base grew 12% to nearly 12,000 systems worldwide, and revenue hit $2.9 billion, up 19% year-over-year. Non-GAAP gross margin expanded to 70%. Yet none of that has stopped the stock's slide.

We break down Intuitive Surgical's revenue mix between recurring instruments and accessories, systems revenue, and services, and walk through what's actually driving the selloff. That includes the impact of ACA subsidy expirations on elective procedure volume, hospital capital spending trends, GLP-1 headwinds on bariatric surgery, and semiconductor memory cost pressures mentioned on the earnings call. We also cover the Extended Use Program and a recent FDA filing as potential positive catalysts, along with full year 2026 guidance.

Finally, we run a reverse DCF to figure out what growth rate is actually priced into ISRG stock today, and whether this sets up as a legitimate buy-the-dip opportunity for long-term investors or if there's more downside ahead.

Semi Insider members get access to CSI's research platform and tools, plus deeper research as it happens. Join at chipstockinvestor.com.

Get 15% off your fiscal.ai membership with our link: fiscal.ai/csi

This content is for general information or entertainment only and is not specific or individual investment advice. Forecasts and information presented may not develop as predicted, and there is no guarantee any strategies presented will be successful. All investing involves risk, and you could lose some or all of your principal. CSI owns shares of Intuitive Surgical.